Background: Estimating distant recurrence (DR) risk among women with estrogen receptor–
positive (ER+), human epidermal growth factor receptor 2 (HER2)–negative early breast …

Introduction EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of
distant recurrence in patients with estrogen receptor-positive (ER+), human epidermal …

Gene expression profiles provide important information about the biology of breast tumors
and can be used to develop prognostic tests. However, the implementation of quantitative …

Biochemical evidence of acute myocardial infarction (AMI) is delayed by the delay of
appearance of serum cardiac markers in the blood after myocardial injury. Heart-type fatty …

Background EndoPredict (EP) is a clinically validated multianalyte gene expression test to
predict distant metastasis in ER-positive, HER2-negative breast cancer treated with …

The development of optimized therapy strategies against malignant tumors is critically
dependent on the assessment of tissue-based biomarkers in routine diagnostic tissue …

There are several prognostic multigene-based tests for managing breast cancer (BC), but
limited data comparing them in the same cohort. We compared the prognostic performance …

Aim This study compared the perfomance of the RNA-based EndoPredict multigene test on
core biopsies and surgical breast cancer specimens and analysed the influence of biopsy …

Although receiving adjuvant chemotherapy after radical surgery, a disappointing proportion
of patients with colorectal cancer will develop tumor recurrence. Probability of relapse is …

Several multigene tests have been developed for breast cancer patients to predict the
individual risk of recurrence. Most of the first generation tests rely on proliferation-associated …